Steer A, Chemlal D, Varlet E, Machura A, Kassambara A, Alaterre E, Requirand G, Robert N, Hirtz C, De Boussac H, Bruyer A, Moreaux J. P843: Metabolomic characterization of human multiple myeloma cell line to study tumor resistance to different classes of therapeutic agents. Hemasphere. 2022. Download the PDF
Summary of the Study
Drug resistance in multiple myeloma (MM) often results from tumor plasticity and survival mechanisms that adapt to therapeutic stress. This study sought to characterize the metabolic phenotype of MM cell lines and link it to therapeutic resistance.
A panel of 20 human MM cell lines (HMCLs) was assessed for metabolic activity using Seahorse XFe96 Mito Stress Assay. Measures included:
- Oxygen consumption rate (OCR)
- Extracellular acidification rate (ECAR)
- Spare respiratory capacity (SRC)
Transcriptomic profiling (RNAseq) was then used to develop a gene-based metabolomic score derived from 112 glycolytic and OxPhos-related genes.
Key findings
- Cell lines showed distinct metabolic dependencies (glycolytic vs mitochondrial)
- The metabolomic score correlated strongly with functional metabolic readouts
- In two independent patient cohorts (MMRF CoMMpass, E-MTAB-362), high metabolomic score predicted poor overall survival
- High mitochondrial ATP production correlated with resistance to proteasome inhibitors (P = 0.023)
Alboukadel Kassambara contributed to the transcriptomic data integration, score modeling, and clinical prognostic analyses, helping validate the metabolomic score across functional and patient datasets.
Citation
Publication: In Hemasphere (Poster Abstract)
Date: June 23, 2022
Type: Poster Presentation
PDF: Download the PDF
Scientific Contributions
Here are more scientific abstracts authored or co-authored by Alboukadel Kassambara. These contributions span computational biology, bioinformatics, biostatistics, machine learning, and multi-omics, with a focus on immuno-oncology and translational research.
